Duaklir Pressair is a drug owned by Astrazeneca. It contains the active ingredients Aclidinium Bromide and Formoterol Fumarate. This drug was first authorized for market use on March 29, 2019, and it currently holds a total of 5 drug patents.
The generics of Duaklir Pressair are likely to be released after March 13, 2029. This anticipated release date takes into account the expiration of the drug's last patent - US10085974 & US11000517 - on the same date. This might suggest a potential opportunity for a Para IV filing, which could expedite the availability of Duaklir Pressair generic.
Duaklir Pressair is widely used as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The drug's effectiveness is largely due to its two active ingredients: Aclidinium Bromide and Formoterol Fumarate.
Duaklir Pressair has a total of 5 patents. The last patent (US10085974 & US11000517), which is set to expire on March 13, 2029, is likely to dictate the release date for Duaklir Pressair's generic version. Below are the details of the patents: